Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) by 106.1% during the third quarter, HoldingsChannel.com reports. The firm owned 95,244 shares of the company’s stock after buying an additional 49,028 shares during the period. JPMorgan Chase & Co.’s holdings in Atea Pharmaceuticals were worth $319,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in AVIR. BML Capital Management LLC lifted its holdings in Atea Pharmaceuticals by 4.3% during the 3rd quarter. BML Capital Management LLC now owns 6,650,000 shares of the company’s stock worth $22,278,000 after buying an additional 274,379 shares during the last quarter. FMR LLC raised its position in shares of Atea Pharmaceuticals by 2.8% during the 3rd quarter. FMR LLC now owns 6,618,297 shares of the company’s stock valued at $22,171,000 after acquiring an additional 182,174 shares in the last quarter. State Street Corp boosted its holdings in Atea Pharmaceuticals by 0.7% in the third quarter. State Street Corp now owns 1,733,486 shares of the company’s stock worth $5,807,000 after purchasing an additional 11,566 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Atea Pharmaceuticals by 8.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 650,157 shares of the company’s stock worth $2,178,000 after purchasing an additional 50,794 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Atea Pharmaceuticals by 55.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 594,360 shares of the company’s stock valued at $1,968,000 after buying an additional 211,428 shares during the period. 86.67% of the stock is currently owned by hedge funds and other institutional investors.

Atea Pharmaceuticals Stock Down 0.3 %

Shares of AVIR stock opened at $2.99 on Friday. The company has a market cap of $252.54 million, a P/E ratio of -1.44 and a beta of 0.20. The business has a 50 day moving average of $3.23 and a two-hundred day moving average of $3.45. Atea Pharmaceuticals, Inc. has a 52 week low of $2.75 and a 52 week high of $4.60.

Atea Pharmaceuticals (NASDAQ:AVIR) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.13. During the same period in the prior year, the company earned ($0.40) EPS. Analysts expect that Atea Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Insider Activity at Atea Pharmaceuticals

In other news, Director Franklin M. Berger sold 359,606 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the transaction, the director now directly owns 451,897 shares of the company’s stock, valued at approximately $1,287,906.45. This trade represents a 44.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 17.80% of the stock is currently owned by insiders.

Atea Pharmaceuticals Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.